vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and Target Hospitality Corp. (TH). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $73.5M, roughly 1.2× Target Hospitality Corp.). On growth, Target Hospitality Corp. posted the faster year-over-year revenue change (22.0% vs 17.7%). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 0.7%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Target Hospitality is a company that provides workforce lodging and other temporary, modular housing used for oil, gas and mining operations; large-scale events; and disaster relief. Target Hospitality is based in The Woodlands, Texas, and also has offices in Williston, North Dakota; Denver, Colorado; Calgary, Alberta.
IOVA vs TH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $73.5M |
| Net Profit | — | $-14.9M |
| Gross Margin | 67.4% | 9.6% |
| Operating Margin | -84.7% | -22.9% |
| Net Margin | — | -20.3% |
| Revenue YoY | 17.7% | 22.0% |
| Net Profit YoY | — | -219.1% |
| EPS (diluted) | — | $-0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $73.5M | ||
| Q3 25 | $67.5M | $91.6M | ||
| Q2 25 | $60.0M | $54.9M | ||
| Q1 25 | $49.3M | $54.9M | ||
| Q4 24 | $73.7M | $60.2M | ||
| Q3 24 | $58.6M | $65.8M | ||
| Q2 24 | $31.1M | $67.5M | ||
| Q1 24 | $715.0K | $72.4M |
| Q4 25 | — | $-14.9M | ||
| Q3 25 | $-91.3M | $-795.0K | ||
| Q2 25 | $-111.7M | $-14.9M | ||
| Q1 25 | $-116.2M | $-6.5M | ||
| Q4 24 | — | $12.5M | ||
| Q3 24 | $-83.5M | $20.0M | ||
| Q2 24 | $-97.1M | $18.4M | ||
| Q1 24 | $-113.0M | $20.4M |
| Q4 25 | 67.4% | 9.6% | ||
| Q3 25 | 43.0% | 19.6% | ||
| Q2 25 | 5.5% | -0.6% | ||
| Q1 25 | -0.8% | 32.7% | ||
| Q4 24 | 68.7% | 61.5% | ||
| Q3 24 | 46.2% | 68.7% | ||
| Q2 24 | -0.8% | 69.4% | ||
| Q1 24 | — | 67.8% |
| Q4 25 | -84.7% | -22.9% | ||
| Q3 25 | -140.7% | 0.1% | ||
| Q2 25 | -189.8% | -30.8% | ||
| Q1 25 | -245.8% | -2.0% | ||
| Q4 24 | -117.5% | 34.5% | ||
| Q3 24 | -152.1% | 42.5% | ||
| Q2 24 | -327.6% | 43.8% | ||
| Q1 24 | -16464.6% | 42.0% |
| Q4 25 | — | -20.3% | ||
| Q3 25 | -135.3% | -0.9% | ||
| Q2 25 | -186.2% | -27.2% | ||
| Q1 25 | -235.5% | -11.8% | ||
| Q4 24 | — | 20.8% | ||
| Q3 24 | -142.7% | 30.4% | ||
| Q2 24 | -312.2% | 27.2% | ||
| Q1 24 | -15800.8% | 28.2% |
| Q4 25 | — | $-0.14 | ||
| Q3 25 | — | $-0.01 | ||
| Q2 25 | $-0.33 | $-0.15 | ||
| Q1 25 | $-0.36 | $-0.07 | ||
| Q4 24 | $-0.24 | $0.12 | ||
| Q3 24 | $-0.28 | $0.20 | ||
| Q2 24 | $-0.34 | $0.18 | ||
| Q1 24 | $-0.42 | $0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $8.3M |
| Total DebtLower is stronger | — | $1.7M |
| Stockholders' EquityBook value | $698.6M | $389.3M |
| Total Assets | $913.2M | $530.2M |
| Debt / EquityLower = less leverage | — | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $8.3M | ||
| Q3 25 | $300.8M | $30.4M | ||
| Q2 25 | $301.2M | $19.2M | ||
| Q1 25 | $359.7M | $34.5M | ||
| Q4 24 | $323.8M | $190.7M | ||
| Q3 24 | $397.5M | $177.7M | ||
| Q2 24 | $412.5M | $154.3M | ||
| Q1 24 | $356.2M | $124.3M |
| Q4 25 | — | $1.7M | ||
| Q3 25 | — | $2.0M | ||
| Q2 25 | — | $26.3M | ||
| Q1 25 | — | $42.9M | ||
| Q4 24 | — | $1.5M | ||
| Q3 24 | — | $994.0K | ||
| Q2 24 | — | $1.1M | ||
| Q1 24 | — | $179.9M |
| Q4 25 | $698.6M | $389.3M | ||
| Q3 25 | $702.3M | $402.4M | ||
| Q2 25 | $698.5M | $401.3M | ||
| Q1 25 | $767.9M | $415.3M | ||
| Q4 24 | $710.4M | $421.1M | ||
| Q3 24 | $773.5M | $417.6M | ||
| Q2 24 | $768.5M | $397.2M | ||
| Q1 24 | $680.0M | $375.5M |
| Q4 25 | $913.2M | $530.2M | ||
| Q3 25 | $904.9M | $541.2M | ||
| Q2 25 | $907.4M | $533.7M | ||
| Q1 25 | $966.7M | $562.5M | ||
| Q4 24 | $910.4M | $725.8M | ||
| Q3 24 | $991.1M | $709.8M | ||
| Q2 24 | $964.3M | $697.0M | ||
| Q1 24 | $869.8M | $687.2M |
| Q4 25 | — | 0.00× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.10× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.48× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $5.7M |
| Free Cash FlowOCF − Capex | $-61.9M | — |
| FCF MarginFCF / Revenue | -71.3% | — |
| Capex IntensityCapex / Revenue | 10.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $5.7M | ||
| Q3 25 | $-78.7M | $53.4M | ||
| Q2 25 | $-67.4M | $11.1M | ||
| Q1 25 | $-103.7M | $3.9M | ||
| Q4 24 | $-73.3M | $30.6M | ||
| Q3 24 | $-59.0M | $31.4M | ||
| Q2 24 | $-98.4M | $39.1M | ||
| Q1 24 | $-122.3M | $50.6M |
| Q4 25 | $-61.9M | — | ||
| Q3 25 | $-89.5M | — | ||
| Q2 25 | $-74.9M | — | ||
| Q1 25 | $-109.9M | $-11.6M | ||
| Q4 24 | $-77.5M | — | ||
| Q3 24 | $-61.3M | — | ||
| Q2 24 | $-98.9M | — | ||
| Q1 24 | $-126.5M | — |
| Q4 25 | -71.3% | — | ||
| Q3 25 | -132.7% | — | ||
| Q2 25 | -124.9% | — | ||
| Q1 25 | -222.8% | -21.1% | ||
| Q4 24 | -105.1% | — | ||
| Q3 24 | -104.6% | — | ||
| Q2 24 | -317.9% | — | ||
| Q1 24 | -17685.3% | — |
| Q4 25 | 10.7% | — | ||
| Q3 25 | 16.1% | — | ||
| Q2 25 | 12.4% | — | ||
| Q1 25 | 12.6% | 28.2% | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 3.9% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 583.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.44× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.13× | ||
| Q1 24 | — | 2.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
TH
| Services | $40.9M | 56% |
| Hospitality And Facilities Services South | $32.6M | 44% |
